{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:09:17Z","timestamp":1765008557866,"version":"3.46.0"},"reference-count":50,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,10,8]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypertension combined with diabetes and hypokalemia is more likely to develop hyperaldosteronism and is at higher risk of cardiovascular events. There is evidence that activation of aldosterone and mineralocorticoid receptors may play a significant role in the occurrence of cardiovascular events in patients with hypertension and diabetes. Clinical studies have demonstrated that spironolactone can reduce the incidence of cardiovascular events in patients with chronic kidney diseases or severe heart failure. However, the effect of spironolactone on cardiovascular risk in patients with hypertension and glucose metabolism disorders (GMD) and low potassium has been scarcely studied. Therefore, this study aims to evaluate whether add-on spironolactone (conventional antihypertensive drugs alone vs conventional antihypertensive drugs+spironolactone) can reduce the morbidity and mortality of cardiovascular events in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this multicentre, randomised, parallel-controlled study, a total of 7140 hypertensive patients aged 45\u201375 years with GMD and low potassium will be randomised in a 1:1 manner to the control or the spironolactone group (20\u2009mg\/day or with a maximum dose of 40\u2009mg). The primary objective is to estimate the difference in the HR of composite cardiovascular events between the two groups. We will also assess the effects of spironolactone on individual cardiovascular events and the progression of diabetes and renal dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This protocol was approved by the Independent Ethics Committee of People\u2019s Hospital of Xinjiang Uygur Autonomous Region (no. 2020020618). The results will be disseminated in peer-reviewed journals and at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2000028909.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-038694","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T03:19:00Z","timestamp":1605842340000},"page":"e038694","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-8566","authenticated-orcid":false,"given":"Nanfang","family":"Li","sequence":"first","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-0331","authenticated-orcid":false,"given":"Mengyue","family":"Lin","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"},{"name":"Xinjiang Medical University, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulalibieke","family":"Heizhati","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"},{"name":"Xinjiang Medical University, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Luo","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jina","family":"Yili","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hong","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Yao","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"2025120600053056000_10.11.e038694.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.5.1863"},{"key":"2025120600053056000_10.11.e038694.2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2854"},{"key":"2025120600053056000_10.11.e038694.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60834-X"},{"key":"2025120600053056000_10.11.e038694.4","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.32"},{"key":"2025120600053056000_10.11.e038694.5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"key":"2025120600053056000_10.11.e038694.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2025120600053056000_10.11.e038694.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.362"},{"key":"2025120600053056000_10.11.e038694.8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/10641963.2016.1182176","article-title":"Evaluation of insulin sensitivity and secretion in primary aldosteronism","volume":"38","author":"Watanabe","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"2025120600053056000_10.11.e038694.9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025120600053056000_10.11.e038694.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1293"},{"key":"2025120600053056000_10.11.e038694.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00434.x"},{"key":"2025120600053056000_10.11.e038694.12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","article-title":"Epidemiology of cardiovascular disease in China: current features and implications","volume":"16","author":"Zhao","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2025120600053056000_10.11.e038694.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0918"},{"key":"2025120600053056000_10.11.e038694.14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/HYPERTENSIONAHA.118.11063","article-title":"Impacts of prediabetes mellitus alone or plus hypertension on the coronary severity and cardiovascular outcomes","volume":"71","author":"Liu","year":"2018","journal-title":"Hypertension"},{"key":"2025120600053056000_10.11.e038694.15","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can J Cardiol"},{"key":"2025120600053056000_10.11.e038694.16","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.12.8.573"},{"key":"2025120600053056000_10.11.e038694.17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10641963.2016.1151526","article-title":"Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus","volume":"38","author":"Karashima","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"2025120600053056000_10.11.e038694.18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/10641963.2012.712175","article-title":"Prevalence of primary aldosteronism in hypertensive subjects with hyperglycemia","volume":"35","author":"Li","year":"2013","journal-title":"Clin Exp Hypertens"},{"key":"2025120600053056000_10.11.e038694.19","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2011.245"},{"key":"2025120600053056000_10.11.e038694.20","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283638b1a"},{"key":"2025120600053056000_10.11.e038694.21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/hr.2013.74","article-title":"Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist","volume":"36","author":"Sato","year":"2013","journal-title":"Hypertens Res"},{"key":"2025120600053056000_10.11.e038694.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.228"},{"key":"2025120600053056000_10.11.e038694.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2007.09.001"},{"key":"2025120600053056000_10.11.e038694.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43124"},{"key":"2025120600053056000_10.11.e038694.25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1291318"},{"key":"2025120600053056000_10.11.e038694.26","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.76"},{"key":"2025120600053056000_10.11.e038694.27","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0905"},{"key":"2025120600053056000_10.11.e038694.28","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1650533"},{"key":"2025120600053056000_10.11.e038694.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025120600053056000_10.11.e038694.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0972-5"},{"key":"2025120600053056000_10.11.e038694.31","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e31816d78e9"},{"key":"2025120600053056000_10.11.e038694.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"2025120600053056000_10.11.e038694.33","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09421209"},{"key":"2025120600053056000_10.11.e038694.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"2025120600053056000_10.11.e038694.35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijcard.2015.05.167","article-title":"Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy","volume":"202","author":"Chung","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025120600053056000_10.11.e038694.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025120600053056000_10.11.e038694.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08090-X"},{"key":"2025120600053056000_10.11.e038694.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"2025120600053056000_10.11.e038694.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.046"},{"key":"2025120600053056000_10.11.e038694.40","article-title":"The story of spironolactones from 1957 to now: from sodium balance to inflammation","volume":"33 Suppl 66","author":"Sabbadin","year":"2016","journal-title":"G Ital Nefrol"},{"key":"2025120600053056000_10.11.e038694.41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.117.10437","article-title":"Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging","volume":"71","author":"Kim","year":"2018","journal-title":"Hypertension"},{"key":"2025120600053056000_10.11.e038694.42","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3282f56854"},{"key":"2025120600053056000_10.11.e038694.43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq254"},{"key":"2025120600053056000_10.11.e038694.44","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0155"},{"key":"2025120600053056000_10.11.e038694.45","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-016-1987-5","article-title":"Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population","volume":"9","author":"Djoumessi","year":"2016","journal-title":"BMC Res Notes"},{"key":"2025120600053056000_10.11.e038694.46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J Clin Hypertens"},{"key":"2025120600053056000_10.11.e038694.47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.809194"},{"key":"2025120600053056000_10.11.e038694.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.066"},{"key":"2025120600053056000_10.11.e038694.49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64093."},{"key":"2025120600053056000_10.11.e038694.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-038694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:05:40Z","timestamp":1765008340000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-038694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,19]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-038694"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-038694","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}